Ustekinumab – eine Standortbestimmung [Ustekinumab - Current position]

Details

Serval ID
serval:BIB_7B29531A25E1
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Ustekinumab – eine Standortbestimmung [Ustekinumab - Current position]
Journal
Zeitschrift fur Gastroenterologie
Author(s)
Siegmund B., Högenauer C., Novacek G., Petritsch W., Reinisch W., Schoepfer A., Schreiber S., Vavricka S., Bokemeyer B.
Working group(s)
für die IBD-Dach-Gruppe
ISSN
1439-7803 (Electronic)
ISSN-L
0044-2771
Publication state
Published
Issued date
09/2018
Peer-reviewed
Oui
Volume
56
Number
9
Pages
1077-1086
Language
german
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The present review by the IBD-Dach group provides a comprehensive summary of the mode of action, clinical development, approval, efficacy and safety aspects of the novel anti-p40 antibody Ustekinumab. The review provides current data, including the large clinical trials as well as smaller case series and work outside the field of inflammatory bowel diseases for shedding more light into special situations. Together, the data indicate that Ustekinumab shows clinical efficacy as well as a good safety profile for the treatment of Crohn's disease.
Keywords
Crohn Disease/drug therapy, Humans, Inflammatory Bowel Diseases/drug therapy, Treatment Outcome, Ustekinumab/adverse effects, Ustekinumab/pharmacology, Ustekinumab/therapeutic use
Pubmed
Web of science
Create date
21/08/2018 8:49
Last modification date
12/09/2019 5:10
Usage data